Adverum Biotechnologies

Adverum Biotechnologies is a United States biotechnology company whose research has focused on gene therapies for serious ocular and rare diseases. The company was founded in 2006 as Avalanche Biotechnologies by Tom Chalberg, Mark Blumenkranz, Mitchell Finer, and Steven Schwartz. Its development model has centered on viral-vector delivery, particularly adeno-associated virus technology, with the goal of providing durable treatment from a single administration rather than requiring frequent chronic dosing. The company became publicly traded after an initial public offering in 2014. Its early clinical work included ophthalmic programs, but the company encountered investor and clinical uncertainty after early-stage trial data were viewed as disappointing. Tom Chalberg stepped down as chief executive officer in 2015, approximately one year after the IPO. In 2016, Avalanche acquired Annapurna Therapeutics and changed its corporate name to Adverum Biotechnologies. The transaction also led to a Nasdaq ticker change from AAVL to ADVM. Amber Salzman, previously Annapurna's chief executive, became Adverum's chief executive later that year. Adverum's best-known investigational program has been ixoberogene soroparvovec, commonly called Ixo-vec and formerly designated ADVM-022. The ophthalmic gene-therapy candidate has been studied for retinal disorders, including diabetic macular edema and wet age-related macular degeneration. The program uses an adeno-associated viral vector administered by intravitreal injection to deliver genetic material intended to support production of a therapeutic protein in the eye. It has remained an investigational program rather than an approved commercial medicine. The company has also pursued rare-disease applications. In January 2022, the United States Food and Drug Administration granted orphan-drug designation to ADVM-062 for blue-cone monochromacy. The candidate was designed for a single intravitreal administration and intended to deliver a functional copy of the OPN1LW gene. In September 2022, Adverum reported dosing the first patient in the LUNA Phase 2 clinical trial, which evaluated Ixo-vec in wet age-related macular degeneration. Adverum's trajectory has been shaped by clinical findings, safety monitoring, leadership changes, financing requirements and the challenge of translating gene-therapy technology into durable, commercially viable treatments. In 2019, investor concern about vision deterioration and reports of ocular inflammation following early Ixo-vec-related data were associated with a sharp decline in the company's share price. The company subsequently continued clinical development under different leadership, with Laurent Fischer becoming chief executive in 2020. Publicly available reference material also reports an announced acquisition by Eli Lilly and Company in December 2025; the completed status and resulting corporate structure require verification against current company and regulatory filings.

Adverum Biotechnologies began in 2006 as Avalanche Biotechnologies. The company was founded by Tom Chalberg, Mark Blumenkranz, Mitchell Finer and Steven Schwartz to develop gene-based treatments for diseases with significant unmet medical need. Its scientific strategy emphasized viral vectors, especially adeno-associated virus, as a means of delivering therapeutic genetic material to selected tissues. Ophthalmology became a major focus because the eye can be accessed locally and may permit targeted administration of gene therapies. Avalanche became a public company through an initial public offering in 2014, raising $102 million according to the cited reference material. The company then faced pressure following early clinical results. In 2015, after Phase IIa results were characterized as uncertain, co-founder and chief executive Tom Chalberg stepped down. The leadership change occurred during a period when investors were reassessing the clinical and commercial potential of the company's initial programs. A major strategic transition came in 2016, when Avalanche acquired Annapurna Therapeutics. Following the acquisition, the company changed its name to Adverum Biotechnologies and changed its Nasdaq ticker from AAVL to ADVM. Amber Salzman, Annapurna's former chief executive, became Adverum's chief executive in October 2016. The transaction broadened the company's gene-therapy ambitions and helped establish the Adverum identity under which its later ophthalmic programs were developed. Leadership changed again in 2018. Salzman left the company in May, while Chief Medical Officer Athena Countouriotis resigned after less than a year in the position. Leone Patterson became chief executive in October 2018. During this period, Adverum continued to develop ocular gene-therapy candidates, including the program later known as ixoberogene soroparvovec, or Ixo-vec, formerly ADVM-022. In September 2019, Adverum released six-month data from the first cohort of an early-stage clinical trial. The announcement was followed by investor concern about deterioration in participants' vision and reports of ocular inflammation. The company's share price fell sharply, reportedly by about 50 percent. These events illustrated the clinical and safety risks associated with intraocular gene therapy and became an important part of the company's development history, although the cited reference does not establish a finding of misconduct or a formal scandal. Laurent Fischer replaced Patterson as chief executive in 2020. Under subsequent development efforts, Adverum continued pursuing gene therapies for retinal disorders. In January 2022, the FDA granted orphan-drug designation to ADVM-062 for blue-cone monochromacy. The candidate was designed for a single intravitreal administration to deliver a functional copy of the OPN1LW gene, reflecting the company's expansion beyond more common retinal diseases into rare ophthalmic conditions. In September 2022, Adverum announced that the first patient had been dosed in the LUNA Phase 2 clinical trial. LUNA evaluated Ixo-vec for wet age-related macular degeneration, a major cause of vision loss. Ixo-vec and related programs remained investigational, and the company's business continued to depend on clinical evidence, regulatory decisions, financing and potential partnerships rather than on revenue from approved products. The supplied reference material reports an announcement in December 2025 that Eli Lilly and Company had acquired Adverum. Because the material does not provide transaction terms or independently confirm closing, the post-announcement corporate status should be checked against up-to-date regulatory filings and official company communications.

1. 2025Reported acquisition by Eli Lilly

   The supplied reference material reports an acquisition announcement by Eli Lilly and Company in December 2025; completion requires verification.

   Source
2. 2022ADVM-062 receives orphan-drug designation

   The FDA granted orphan-drug designation to ADVM-062 for blue-cone monochromacy.

   Source
3. 2022LUNA Phase 2 trial begins dosing

   Adverum announced dosing of the first patient in the LUNA Phase 2 trial for wet age-related macular degeneration.

   Source
4. 2019Early Ixo-vec data disclosed

   Six-month data from the first cohort of a Phase 1 study were announced amid concerns about vision deterioration and ocular inflammation.

   Source
5. 2016Annapurna acquisition and corporate rebranding

   Avalanche acquired Annapurna Therapeutics, adopted the Adverum Biotechnologies name and changed its Nasdaq ticker from AAVL to ADVM.

   Source
6. 2015Co-founder leaves chief executive role

   Tom Chalberg stepped down as chief executive following uncertain Phase IIa results.

   Source
7. 2014Initial public offering

   The company went public and raised $102 million, according to the cited reference material.

   Source
8. 2006Company founded as Avalanche Biotechnologies

   Avalanche Biotechnologies was founded by Tom Chalberg, Mark Blumenkranz, Mitchell Finer and Steven Schwartz.

   Source

Clinical-stage gene-therapy biotechnology company focused on serious ocular and rare diseases

• Ixoberogene soroparvovecInvestigational ophthalmic gene therapy

  Ixoberogene soroparvovec, known as Ixo-vec and formerly designated ADVM-022, is Adverum's principal investigational ophthalmic gene-therapy program. It uses an adeno-associated viral vector delivered by intravitreal administration to introduce therapeutic genetic material into the eye. The program has been studied in retinal diseases including diabetic macular edema and wet age-related macular degeneration. It is not identified in the supplied material as an approved or marketed medicine.

• ADVM-062Investigational rare-disease gene therapy

  ADVM-062 is an investigational gene-therapy candidate developed for blue-cone monochromacy, a rare inherited retinal disorder. The program was designed around a single intravitreal administration intended to deliver a functional copy of the OPN1LW gene. The FDA granted the candidate orphan-drug designation in January 2022. The supplied material does not establish that ADVM-062 has received marketing approval.

• 2022Advance ADVM-062 for blue-cone monochromacyProduct launch

  Adverum was seeking applications for its gene-delivery technology in rare inherited retinal disease.

  What changed. The company advanced ADVM-062, designed for a single intravitreal administration, and received FDA orphan-drug designation for blue-cone monochromacy.

  Aftermath. The designation supported continued development of the investigational program; no approval or commercial launch is established in the supplied material.

  Source
• 2022Begin LUNA Phase 2 developmentProduct launch

  Adverum was evaluating Ixo-vec as a potentially durable treatment for wet age-related macular degeneration.

  What changed. The company announced that the first patient had been dosed in the LUNA Phase 2 clinical trial.

  Aftermath. The program remained in clinical development and had not been identified as an approved commercial product in the supplied sources.

  Source
• 2016Acquire Annapurna and rebrand as AdverumM&A

  Avalanche Biotechnologies pursued a strategic combination with Annapurna Therapeutics as it continued building a gene-therapy platform.

  What changed. The company acquired Annapurna, changed its name to Adverum Biotechnologies and changed its Nasdaq ticker from AAVL to ADVM.

  Aftermath. Amber Salzman, Annapurna's former chief executive, became Adverum's chief executive in October 2016.

  Source

• 2025Eli Lilly acquisition announcement

  Reference material reports that Adverum was announced as acquired by Eli Lilly and Company in December 2025. The completion and terms of the transaction require confirmation from current filings.

  M&A
  Source
• 2022FDA grants orphan-drug designation to ADVM-062

  The FDA granted orphan-drug designation to ADVM-062, an investigational gene therapy intended for blue-cone monochromacy.

  RegulationProduct launch
  Source
• 2022First patient dosed in the LUNA Phase 2 trial

  Adverum reported dosing the first participant in LUNA, a Phase 2 study evaluating Ixo-vec for wet age-related macular degeneration.

  Product launchProduct generation
  Source
• 2019Adverum reports early Ixo-vec data amid ocular safety concerns

  After the company announced six-month data from the first cohort of a Phase 1 trial, reports of vision deterioration and ocular inflammation prompted investor concern and were associated with an approximately 50% share-price decline.

  OtherProduct generation
  Source
• 2016Avalanche acquires Annapurna and adopts the Adverum name

  Avalanche Biotechnologies acquired Annapurna Therapeutics, changed its corporate name to Adverum Biotechnologies and changed its Nasdaq ticker from AAVL to ADVM.

  M&ALeadership changeOther
  Source
• 2016Amber Salzman becomes chief executive

  Amber Salzman, who had led Annapurna Therapeutics, became chief executive of the renamed company.

  Leadership change
  Source
• 2015Tom Chalberg steps down as chief executive after early clinical uncertainty

  Tom Chalberg left the chief executive role after Phase IIa results from an early program were viewed by investors as uncertain or disappointing.

  Leadership changeOther
  Source

1. Adverum Biotechnologies